Dhanya R Shenoy, N. Navakumar, Vidyalekshmy R, Brinda Sabu, Roshini Ambat, Sajitlh Mohan, Lumiya Malik, Suresh Chandran
{"title":"妊娠期肌无力:通过精准护理实现最佳疗效--来自南印度的系列病例及文献综述","authors":"Dhanya R Shenoy, N. Navakumar, Vidyalekshmy R, Brinda Sabu, Roshini Ambat, Sajitlh Mohan, Lumiya Malik, Suresh Chandran","doi":"10.36106/gjra/2506207","DOIUrl":null,"url":null,"abstract":"Introduction: Myasthenia Gravis (MG) is an autoimmune neuromuscular disorder affecting skeletal\nmuscles, particularly in women of reproductive age. Though uncommon with a prevalence of only 0.3 to\n2.8 per 100,000, the incidence peaks during 2nd and 3rd decades of life, and can have signicant impact in pregnancy. The\ncourse of the disease in pregnancy is not entirely understood. Methodology: A retrospective case series analysis of 4 cases\nwere carried out for a period of 5 years from 2018 in a tertiary care centre in South India to identify and describe the disease\ncourse in pregnancy and effect of disease in the pregnant women and their fetuses. From this study, we aimed to describe the\ndisease course of MG in pregnancy and formulate an optimal management plan, learning from our experience. Results: All\npatients included in the study were in a state of remission prior to conception. With vigilant monitoring and collaborative\nmultidisciplinary approach, two patients successfully carried their pregnancies to term without encountering any\ncomplications, maintaining a stable course throughout the antenatal, intrapartum, and postpartum periods. However, one\npatient experienced an acute exacerbation upon contracting COVID-19 category C. Subsequently, her pregnancy was\ncomplicated by late-onset fetal growth restriction, preterm premature rupture of membranes (PPROM), preterm birth and\npostpartum exacerbation. Despite these challenges, both maternal and fetal outcomes were favorable, attributed to\nmeticulous surveillance and critical care interventions. Another patient experienced an exacerbation at 10 weeks of gestation\nbut otherwise had an uneventful pregnancy, labour, and postpartum recovery. Conclusion: One third of Myasthenia gravis\npatients can have exacerbations in pregnancy with a small but signicant subset experiencing potentially life threatening\nMyasthenic crisis. All necessary precautions should be pro-actively taken to prevent factors that could trigger a myasthenic\ncrisis, including cautious drug selection during anaesthesia and the avoidance of medications that may exacerbate MG during\nacute infections. Caesarean section should be for obstetric indications only. Managing myasthenia gravis in pregnancy is\nquite challenging and requires multidisciplinary input with close monitoring and follow up.","PeriodicalId":12664,"journal":{"name":"Global journal for research analysis","volume":"79 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-02-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"MYASTHENIA GRAVIS IN PREGNANCY: ACHIEVING OPTIMAL OUTCOMES THROUGH PRECISION CARE – A CASE SERIES FROM SOUTH INDIA & REVIEW OF LITERATURE\",\"authors\":\"Dhanya R Shenoy, N. Navakumar, Vidyalekshmy R, Brinda Sabu, Roshini Ambat, Sajitlh Mohan, Lumiya Malik, Suresh Chandran\",\"doi\":\"10.36106/gjra/2506207\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: Myasthenia Gravis (MG) is an autoimmune neuromuscular disorder affecting skeletal\\nmuscles, particularly in women of reproductive age. Though uncommon with a prevalence of only 0.3 to\\n2.8 per 100,000, the incidence peaks during 2nd and 3rd decades of life, and can have signicant impact in pregnancy. The\\ncourse of the disease in pregnancy is not entirely understood. Methodology: A retrospective case series analysis of 4 cases\\nwere carried out for a period of 5 years from 2018 in a tertiary care centre in South India to identify and describe the disease\\ncourse in pregnancy and effect of disease in the pregnant women and their fetuses. From this study, we aimed to describe the\\ndisease course of MG in pregnancy and formulate an optimal management plan, learning from our experience. Results: All\\npatients included in the study were in a state of remission prior to conception. With vigilant monitoring and collaborative\\nmultidisciplinary approach, two patients successfully carried their pregnancies to term without encountering any\\ncomplications, maintaining a stable course throughout the antenatal, intrapartum, and postpartum periods. However, one\\npatient experienced an acute exacerbation upon contracting COVID-19 category C. Subsequently, her pregnancy was\\ncomplicated by late-onset fetal growth restriction, preterm premature rupture of membranes (PPROM), preterm birth and\\npostpartum exacerbation. Despite these challenges, both maternal and fetal outcomes were favorable, attributed to\\nmeticulous surveillance and critical care interventions. Another patient experienced an exacerbation at 10 weeks of gestation\\nbut otherwise had an uneventful pregnancy, labour, and postpartum recovery. Conclusion: One third of Myasthenia gravis\\npatients can have exacerbations in pregnancy with a small but signicant subset experiencing potentially life threatening\\nMyasthenic crisis. All necessary precautions should be pro-actively taken to prevent factors that could trigger a myasthenic\\ncrisis, including cautious drug selection during anaesthesia and the avoidance of medications that may exacerbate MG during\\nacute infections. Caesarean section should be for obstetric indications only. Managing myasthenia gravis in pregnancy is\\nquite challenging and requires multidisciplinary input with close monitoring and follow up.\",\"PeriodicalId\":12664,\"journal\":{\"name\":\"Global journal for research analysis\",\"volume\":\"79 2\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Global journal for research analysis\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.36106/gjra/2506207\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global journal for research analysis","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36106/gjra/2506207","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
MYASTHENIA GRAVIS IN PREGNANCY: ACHIEVING OPTIMAL OUTCOMES THROUGH PRECISION CARE – A CASE SERIES FROM SOUTH INDIA & REVIEW OF LITERATURE
Introduction: Myasthenia Gravis (MG) is an autoimmune neuromuscular disorder affecting skeletal
muscles, particularly in women of reproductive age. Though uncommon with a prevalence of only 0.3 to
2.8 per 100,000, the incidence peaks during 2nd and 3rd decades of life, and can have signicant impact in pregnancy. The
course of the disease in pregnancy is not entirely understood. Methodology: A retrospective case series analysis of 4 cases
were carried out for a period of 5 years from 2018 in a tertiary care centre in South India to identify and describe the disease
course in pregnancy and effect of disease in the pregnant women and their fetuses. From this study, we aimed to describe the
disease course of MG in pregnancy and formulate an optimal management plan, learning from our experience. Results: All
patients included in the study were in a state of remission prior to conception. With vigilant monitoring and collaborative
multidisciplinary approach, two patients successfully carried their pregnancies to term without encountering any
complications, maintaining a stable course throughout the antenatal, intrapartum, and postpartum periods. However, one
patient experienced an acute exacerbation upon contracting COVID-19 category C. Subsequently, her pregnancy was
complicated by late-onset fetal growth restriction, preterm premature rupture of membranes (PPROM), preterm birth and
postpartum exacerbation. Despite these challenges, both maternal and fetal outcomes were favorable, attributed to
meticulous surveillance and critical care interventions. Another patient experienced an exacerbation at 10 weeks of gestation
but otherwise had an uneventful pregnancy, labour, and postpartum recovery. Conclusion: One third of Myasthenia gravis
patients can have exacerbations in pregnancy with a small but signicant subset experiencing potentially life threatening
Myasthenic crisis. All necessary precautions should be pro-actively taken to prevent factors that could trigger a myasthenic
crisis, including cautious drug selection during anaesthesia and the avoidance of medications that may exacerbate MG during
acute infections. Caesarean section should be for obstetric indications only. Managing myasthenia gravis in pregnancy is
quite challenging and requires multidisciplinary input with close monitoring and follow up.